Diligence memo · auto-generated · as of July 2, 2026
Turn Biotechnologies, Inc.
Turn Biotechnologies, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Turn Biotechnologies, Inc. operates in Biotech / Pharma, based in MOUNTAIN VIEW.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Turn Biotechnologies, Inc. has raised $29M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $29M on 2023-08-22.
Most recent recorded round closed around 2023-08-22.
Valuation (modeled)modeled
Provath models Turn Biotechnologies, Inc. at approximately $294M (range $60M–$620M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.11× the median modeled value of Series B Biotech / Pharma companies in 2022–2024 (15 peers) — value vs value, same stage and era. Within the normal band (111% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 2.9 yr ago; this sector typically re-raises about every 15 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
Comparablesmixed
Capital scale ranks ahead of 83% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 85% of those peers.
Closest niche peers: Carbon Biosciences, Inc., Slingshot Biosciences, Inc., Nueva Bio LLC, Telesis Bio Inc., Surf Bio, Inc..
Peoplefiled
6 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.